呲仑帕奈功效与作用

Perampanel is a highly selective, non-competitive AMPA glutamate receptor antagonist developed by Japan's Eisai. By inhibiting the glutamate activity of postsynaptic AMPA receptors, it reduces neural overexcitation and achieves the purpose of preventing and treating epilepsy. Today let’s learn about its functions and effects.

Systematic review of the effectiveness and safety of perampanel in the treatment of refractory partial seizures in epilepsy. Methods: A computer search was performed on PubMed, EBSCO, EMbase, Cochrane Library, Chinese Biomedical Literature Database (CBM), Chinese Journal Full Text Database (CNKI), Chinese Scientific and Technological Journal Full Text Database (VIP) and Wanfang Database to collect randomized controlled trials of perampanel in the treatment of refractory partial seizures in epilepsy. The search time limit was from inception to February 2017, using RevMan. 5.0 software was used to perform meta-analysis on each effect indicator. Results A total of 5 studies were included, totaling 1,500 patients.

The results of the meta-analysis showed that the perampanel group had a complete seizure-free rate [OR=3.75, 95% CI (1.77, 7.93), P=0.0006], and the percentage of patients with a ≥50% reduction in seizure frequency [OR=2 .08, 95% CI (1.69, 2.56), P < 0.001] were higher than those in the placebo group, and the differences were statistically significant; the main adverse reactions of perampanel include dizziness, drowsiness, headache, ataxia, nasopharyngitis, etc.; perampanel 8 The incidence of total adverse reactions in the mg and 12 mg groups was higher than that in the placebo group, and the difference was statistically significant (P<0.05). Conclusion Perampanel can effectively reduce the frequency of epileptic seizures in the treatment of refractory partial seizures, and the adverse reactions are mild, and the patients basically tolerate it.

In 2012, perampanel was approved as an adjuvant treatment for POS; subsequently in 2015, it was approved as an adjuvant treatment for primary generalized tonic-clonic (PGTC) seizures in epilepsy patients 12 years of age and older; and in 2017, it was approved as a monotherapy for partial-onset seizures with or without secondary generalized seizures in patients 12 years of age and older. So far, it has been approved by 55 countries around the world, and more than 200,000 patients have been treated with the drug.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.